Mirum Pharmaceuticals, Inc. (MIRM)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$324.9M
Cash & Equivalents
$228.8M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$7,448M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (3 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
MARALIXIBAT CHLORIDE
LIVMARLI |
APPROVED | Acid Sphingomyelinase Deficiency, Adrenoleukodystrophy, Alagille Syndrome, Alagille Syndrome (ALGS), Bile Acid Synthesis Defect, Bile Acid Synthesis Disorders, Biliary Atresia, Cerebrotendinous Xanthomatosis, Ceroid Lipofuscinosis, Neuronal, 2, Cholestasis, Cholestasis, Intrahepatic, Cholestatic Liver Disease, Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC), Chronic Hepatitis D, Chronic Hepatitis D Infection, CTX, Fabry Disease, Fragile X Syndrome, Gaucher Disease, GM1 Gangliosidosis, Healthy Volunteers, Inborn Errors of Bile Acid Synthesis, Infantile Refsum's Disease, Intrahepatic Cholestasis of Pregnancy, Lysosomal Acid Lipase Deficiency, Metachromatic Leukodystrophy, Mucopolysaccharidosis II, Mucopolysaccharidosis III-B, Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidosis VII, Niemann-Pick Disease, Type C, Non-alcoholic Steatohepatitis, PBC, Peroxisomal Disorders, PFIC - Progressive Familial Intrahepatic Cholestasis, Primary Biliary Cholangitis, Primary Biliary Cirrhosis, |
|
CHENODIOL
CTEXLI |
APPROVED | — |
|
CHOLIC ACID
CHOLBAM |
APPROVED | — |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase3 Readout | — |
| 2026-09-26 | Pdufa | — |
| 2026-10-01 | Phase3 Readout | — |
| 2027-04-01 | Phase2 Readout | — |
| 2027-06-30 | Phase3 Readout | — |
Active Clinical Trials (12)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06193928 | Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | OTHER | Recruiting | 70 |
| NCT03115086 | The REPLACE Registry for Cholbam® (Cholic Acid) | OTHER | Active Not Recruiting | 55 |
| NCT07411716 | Pediatric Evaluation and Registry for Liver Cholestasis in Canada | OTHER | Recruiting | 220 |
| NCT07290257 | Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome ... | PHASE4 | Recruiting | 230 |
| NCT06553768 | Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | PHASE3 | Active Not Recruiting | 90 |
| NCT07298330 | A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4) | PHASE3 | Active Not Recruiting | 80 |
| NCT07454837 | Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide | PHASE3 | Recruiting | 120 |
| NCT06907290 | A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | PHASE3 | Active Not Recruiting | 150 |
| NCT07200908 | A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | PHASE3 | Recruiting | 172 |
| NCT07209462 | Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) | PHASE2 | Recruiting | 60 |
| NCT05050136 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Pr... | PHASE2 | Recruiting | 260 |
| NCT04663308 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Pr... | PHASE2 | Active Not Recruiting | 182 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.